New therapies to blunt this process include targeting enzymes below the cell membrane that serve as strategic nodes for hypertrophy regulation. Rho kinase (ROCK) is activated in cardiac ...

Cardiac hypertrophy is the abnormal enlargement, or thickening, of the heart muscle, resulting from increases in cardiomyocyte size and changes in other heart muscle components, such as ...

Another active area of research in the laboratory focuses on unraveling the mechanisms behind maladaptive, or pathological, and adaptive, or physiological, cardiac hypertrophy. In response to certain ...

Hypertrophic cardiomyopathy (HCM) is the most common genetic cardiovascular condition. It is the leading cause of sudden ...

Aim Differentiating physiological cardiac hypertrophy from pathology is challenging when the athlete presents with extreme anthropometry. While upper normal limits exist for maximal left ventricular ...

Left ventricular hypertrophy can be diagnosed on ECG with good specificity. When the myocardium is hypertrophied, there is a larger mass of myocardium for electrical activation to pass through ...

Background: Atrial function is an integral part of cardiac function that is often neglected. The presence of left ventricule hypertrophy (LVH) due to arterial hypertension may impair atrial function.

For children with severe hypertrophic cardiomyopathy caused by gain-of-function RAS/mitogen-activated protein kinase (MAPK) mutations (RASopathy), trametinib reduces mortality and morbidity.